A recent first-in-human, first-in-class, open-label phase 1 study using rovalpituzumab tesirine, an antibody-drug conjugate directed against DLL3, demonstrated significant antitumor activity in patients with SCLC [18], especially when they have high expression of DLL3. This evidence concerns the gene DLL3 and small cell lung carcinoma.